Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.12
Price-0.94%
-$0.02
1Y
Price
Market Cap
$767.130m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-15079.0%
EBITDA Margin-15800.8%
Net Profit Margin-17685.3%
Free Cash Flow MarginRevenue
$241.524m
+60.1%
1y CAGR+20.0%
3y CAGR+15.0%
5y CAGREarnings
-$389.921m
-1.3%
1y CAGR-11.4%
3y CAGR-15.4%
5y CAGREPS
-$1.23
+4.8%
1y CAGR+4.4%
3y CAGR-0.5%
5y CAGRBook Value
$698.488m
$907.437m
Assets$208.949m
Liabilities$53.166m
DebtDebt to Assets
5.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$323.538m
-5.5%
1y CAGR-15.3%
3y CAGR-12.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company